Columbus Circle Investors grew its stake in shares of Boston Scientific Co. (NYSE:BSX) by 13.5% during the 4th quarter, HoldingsChannel.com reports. The firm owned 1,038,093 shares of the medical equipment provider’s stock after buying an additional 123,452 shares during the quarter. Columbus Circle Investors’ holdings in Boston Scientific were worth $36,686,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors also recently made changes to their positions in the company. We Are One Seven LLC acquired a new position in shares of Boston Scientific during the fourth quarter valued at about $27,000. Ipswich Investment Management Co. Inc. acquired a new position in shares of Boston Scientific during the fourth quarter valued at about $28,000. CWM LLC raised its holdings in shares of Boston Scientific by 54.3% during the fourth quarter. CWM LLC now owns 1,020 shares of the medical equipment provider’s stock valued at $36,000 after purchasing an additional 359 shares during the period. West Oak Capital LLC raised its holdings in shares of Boston Scientific by 40.0% during the fourth quarter. West Oak Capital LLC now owns 1,050 shares of the medical equipment provider’s stock valued at $37,000 after purchasing an additional 300 shares during the period. Finally, Exane Derivatives raised its holdings in shares of Boston Scientific by 116,300.0% during the fourth quarter. Exane Derivatives now owns 1,164 shares of the medical equipment provider’s stock valued at $41,000 after purchasing an additional 1,163 shares during the period. Hedge funds and other institutional investors own 91.60% of the company’s stock.
In other Boston Scientific news, SVP Maulik Nanavaty sold 3,038 shares of the company’s stock in a transaction dated Tuesday, January 15th. The shares were sold at an average price of $35.46, for a total value of $107,727.48. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP David A. Pierce sold 5,000 shares of the company’s stock in a transaction dated Friday, February 1st. The stock was sold at an average price of $38.15, for a total transaction of $190,750.00. Following the completion of the sale, the executive vice president now directly owns 29,201 shares of the company’s stock, valued at $1,114,018.15. The disclosure for this sale can be found here. Insiders sold a total of 91,724 shares of company stock valued at $3,350,373 over the last ninety days. 0.73% of the stock is currently owned by insiders.
Boston Scientific (NYSE:BSX) last issued its quarterly earnings data on Wednesday, February 6th. The medical equipment provider reported $0.39 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.37 by $0.02. Boston Scientific had a net margin of 17.01% and a return on equity of 26.80%. The business had revenue of $2.56 billion during the quarter, compared to the consensus estimate of $2.57 billion. During the same period in the prior year, the firm posted $0.34 EPS. The firm’s quarterly revenue was up 6.4% compared to the same quarter last year. On average, equities analysts expect that Boston Scientific Co. will post 1.56 EPS for the current year.
Several brokerages have recently weighed in on BSX. Canaccord Genuity reiterated a “buy” rating and set a $45.00 price objective on shares of Boston Scientific in a report on Monday. SunTrust Banks reissued a “buy” rating and set a $47.00 target price on shares of Boston Scientific in a research report on Friday, February 8th. Guggenheim reissued a “buy” rating and set a $48.00 target price on shares of Boston Scientific in a research report on Friday, February 8th. Needham & Company LLC reissued a “buy” rating and set a $43.00 target price on shares of Boston Scientific in a research report on Wednesday, February 6th. Finally, Zacks Investment Research raised shares of Boston Scientific from a “sell” rating to a “hold” rating in a research report on Monday, January 7th. Three investment analysts have rated the stock with a hold rating, twenty-two have issued a buy rating and two have issued a strong buy rating to the company’s stock. Boston Scientific has a consensus rating of “Buy” and an average target price of $40.46.
About Boston Scientific
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: Cardiovascular, Rhythm Management, and MedSurg. The company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions therapy products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels; and structural heart therapy systems.
Read More: What are convertible shares?
Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Co. (NYSE:BSX).
Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.